...
首页> 外文期刊>Journal of diabetes research. >Therapeutic Potential of Dioscorea Extract (DA-9801) in Comparison with Alpha Lipoic Acid on the Peripheral Nerves in Experimental Diabetes
【24h】

Therapeutic Potential of Dioscorea Extract (DA-9801) in Comparison with Alpha Lipoic Acid on the Peripheral Nerves in Experimental Diabetes

机译:二十次摘除(DA-9801)的治疗潜力与α硫辛酸对实验糖尿病外周神经相比

获取原文
获取原文并翻译 | 示例

摘要

DA-9801, a mixture of extracts from Dioscorea japonica Thunb. and Dioscorea nipponica Makino, was reported to have neurotrophic activity. Therefore, we investigated the therapeutic potential of DA-9801, in comparison with alpha lipoic acid (ALA), for peripheral nerves preservation in experimental diabetes. Experimental animals were divided into 4 groups, and each group was designated according to the type of treatment administered as follows: normal, DM, DM+DA-9801, and DM+ALA. After 16 weeks, response thresholds to tactile and thermal stimuli were higher in DM+DA-9801 group than in nontreated DM group. This degree of increase in DM+DA-9801 group indicates more therapeutic potency of DA-9801 than ALA. Western blot analysis showed more significant increase in NGF and decrease in TNF-alpha and IL-6 in DM+DA-9801 group than in DM or DM+ALA groups (P < 0.05). IENF density was reduced less significantly in the DM+DA-9801 group than in other DM groups (7.61 +- 0.32, 4.2 + 0.26, and 6.5 +- 0.30 in DM+DA-9801, DM, and DM+ALA, resp., P < 0.05), Mean myelinated axonal area in the sciatic nerves was significantly greater in DM+DA-9801 group than in other DM groups (69.2 +- 5.76, 54.0 +- 6.32, and 63.1 +- 5.41 in DM+DA-9801, DM, and DM+ALA, resp., P < 0.05). ResulLs of this study demonstrated potential therapeuLic applications of DA-9801 for the treatment of diabetic peripheral neuropathy.
机译:DA-9801,来自Dioscorea japonica Thunb的提取物的混合物。据报道,Dioscorea Nipponica Makino有神经营养活性。因此,我们研究了与α硫辛酸(ALA)相比,DA-9801的治疗潜力,用于实验糖尿病中的外周神经保存。将实验动物分成4组,并根据如下施用的治疗类型指定每组:正常,DM,DM + DA-9801和DM + ALA。 16周后,DM + DA-9801组触觉和热刺激的响应阈值高于非生成的DM组。 DM + DA-9801组的这种增加程度表明DA-9801的治疗效力比ALA更多。 Western印迹分析表明,DM + DA-9801组中的NGF和TNF-α和IL-6的降低更显着​​增加,而不是DM或DM + ALA组(P <0.05)。在DM + DA-9801组中,IENF密度显着降低,而不是其他DM组(7.61±0.32,4.2 + 0.26和6.5 + - 0.30,DM + DA-9801,DM和DM + ALA,REB。 ,P <0.05),DM + DA-9801组中坐骨神经中的平均骨髓轴突区域比其他DM组(69.2 + - 5.76,54.0 + - 6.32和63.1 + - 5.41在DM + DA - 9801,DM和DM + ALA,RESP。,P <0.05)。本研究的重建证明DA-9801用于治疗糖尿病外周神经病变的潜在治疗应用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号